Skip to main content
logo
Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
45.33
-0.28 (-0.61%)
Aug 31, 2026, 4:00 PM EDT - Market closed

Novo Nordisk Financials Overview

Millions DKK. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Revenue
78,48896,82379,14474,97676,85778,08785,68371,31168,06065,34965,86358,73154,30053,36748,09245,56641,26542,03138,33335,622
Revenue Growth
2.12%23.99%-7.63%5.14%12.93%19.49%30.09%21.42%25.34%22.45%36.95%28.89%31.59%26.97%25.46%27.91%24.89%24.34%19.28%15.18%
Gross Profit
61,38883,22564,97460,50564,01165,19773,62160,00357,78655,43356,29549,01846,44445,18539,83038,36635,19635,11432,09229,563
Operating Income
33,38959,61835,24133,25433,44938,79147,29933,82231,63431,84628,89026,91323,88825,00717,84720,18418,39119,14714,33115,249
Net Income
20,98948,55726,89120,00626,50329,03428,23027,30120,05025,40721,96322,47819,42819,81413,59214,40513,31814,21010,89212,119
Earnings Per Share
4.7310.916.044.505.966.536.346.124.495.684.915.004.324.393.013.172.933.112.382.63
EPS Growth
-20.61%67.07%-4.66%-26.47%32.74%14.96%29.15%22.40%3.94%29.39%63.07%57.73%47.44%41.16%26.47%20.30%11.41%14.13%18.81%19.23%

Revenue by Segment
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Rybelsus
5,2284,5725,3035,4425,6535,6956,9175,4535,9185,0135,9104,4963,9884,3564,0533,0112,1722,0631,8231,341
Ozempic
31,37527,82531,82530,74431,79932,72133,85329,80428,87527,81030,06523,91222,10119,64016,97616,39014,34912,03510,7168,892
Victoza
1813343995499141,1581,403-3222,2422,1591,7862,2271,8362,8153,3232,9672,7103,3223,8333,615
Long-Acting Insulin
4,4124,2324,7004,2004,4675,3885,1584,0354,7375,1653,7263,6923,3544,1333,9023,9394,1044,7964,6774,416
Premix Insulin
2,7902,3952,5092,3572,6362,8132,8672,5182,4362,9682,1232,2192,4562,7762,3432,7062,5013,0122,6912,844
Fast-Acting Insulin
4,6913,9554,8804,1094,5425,0526,0174,1503,8684,4874,1423,8083,5114,4884,4714,2633,8874,8424,5204,359
Human Insulin
1,0481,0631,3121,3271,1011,7441,8451,8061,5711,7451,9891,6261,9672,0121,9702,0531,8512,3122,0852,391
Other Diabetes Care
704560422421454473512492533583322594667729713798830884816859
Wegovy
22,70220,49121,86420,35419,52817,36019,86617,30411,6599,3779,6149,6487,5184,5632,4461,1571,1811,404782519
Saxenda
4504215817528441,0641,5401,4972,2451,6581,6152,6072,7883,2793,0423,1742,4621,9981,6771,879
Rare Blood Disorders
2,8962,6333,0192,9193,0962,9213,3982,9882,8642,8882,9342,9572,8363,0492,8812,8852,8633,0772,4902,326
Rare Endocrine Disorders
1,5381,1471,8341,3931,4201,3121,9231,2277301,1131,2645429021,1281,6021,7931,9231,8201,7191,805
Other Rare Disease
473435496409403386384359382383373403376399370430432466504376
Revenue (Total)
78,48896,82379,14474,97676,85778,08785,68371,31168,06065,34965,86358,73154,30053,36748,09245,56641,26542,03138,33335,622

Cash & Debt
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Cash & Investments
44,98221,62626,96232,58318,93441,55026,30874,88162,6549,30330,23047,59536,40827,77123,57437,47331,03720,14617,48535,390
Total Debt
140,127146,382130,958101,21499,268118,723102,78756,97257,06026,92827,00626,53725,70425,51825,78425,96925,43425,48026,64513,748
Net Cash (Debt)
-95,145-124,756-103,996-68,631-80,334-77,173-76,47917,9095,594-17,6253,22421,05810,7042,253-2,21011,5045,603-5,334-9,16021,642
Net Cash Growth
--------14.95%-47.74%--83.05%91.04%---46.84%-58.35%--1.24%
Net Cash Per Share
-21.45-28.04-23.37-15.43-18.07-17.36-17.174.021.25-3.940.724.692.380.50-0.492.541.23-1.17-2.004.71

Cash Flow & CapEx
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Operating Cash Flow
55,19924,0847,61946,10741,77424,73012,30143,85050,50314,3149,55140,96628,57729,8147,10124,23923,96123,586-3,01721,507
Capital Expenditures
-12,675-11,311-18,429-13,628-14,661-13,422-16,101-12,119-10,470-8,474-9,407-5,828-5,878-4,693-4,961-3,230-2,435-1,520-2,049-1,175
Free Cash Flow
42,52412,773-10,81032,47927,11311,308-3,80031,73140,0335,84014435,13822,69925,1212,14021,00921,52622,066-5,06620,332
Free Cash Flow Growth
56.84%12.96%-2.36%-32.27%93.63%--9.70%76.37%-76.75%-93.27%67.25%5.45%13.84%-3.33%-8.58%123.95%-26.25%

Margins
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
Gross Margin
78.21%85.96%82.10%80.70%83.29%83.49%85.92%84.14%84.90%84.83%85.47%83.46%85.53%84.67%82.82%84.20%85.29%83.54%83.72%82.99%
Operating Margin
42.54%61.57%44.53%44.35%43.52%49.68%55.20%47.43%46.48%48.73%43.86%45.82%43.99%46.86%37.11%44.30%44.57%45.55%37.39%42.81%
Pretax Margin
34.24%64.21%43.19%34.03%43.98%47.43%41.50%48.22%37.22%48.84%41.94%47.78%44.67%46.35%33.93%39.57%40.70%42.63%34.21%42.42%
Profit Margin
26.74%50.15%33.98%26.68%34.48%37.18%32.95%38.28%29.46%38.88%33.35%38.27%35.78%37.13%28.26%31.61%32.27%33.81%28.41%34.02%
FCF Margin
54.18%13.19%-13.66%43.32%35.28%14.48%-4.44%44.50%58.82%8.94%0.22%59.83%41.80%47.07%4.45%46.11%52.16%52.50%-13.22%57.08%

Dividends
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21
Dividend Per Share
3.750-7.950-3.750-7.900-3.500-6.400-3.000-4.075-2.125-3.450
Dividend Per Share Growth
0%-0.63%-7.14%-23.44%-16.67%-57.05%-41.18%-18.12%----
Dividend Yield
3.76%-3.74%-2.77%-1.94%-1.05%-1.43%-1.37%-1.41%-1.52%-1.54%

Valuation
Chart
Fiscal QuarterQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021
Period EndingJun '26 Mar '26 Dec '25 Sep '25 Jun '25 Mar '25 Dec '24 Sep '24 Jun '24 Mar '24 Dec '23 Sep '23 Jun '23 Mar '23 Dec '22 Sep '22 Jun '22 Mar '22 Dec '21 Sep '21
PE Ratio
11.968.4014.1114.7617.5719.9327.4536.8249.6144.0537.1938.2436.6539.9538.1632.6235.3434.5235.0730.81
P/FCF Ratio
18.0916.65-22.8229.4126.31-44.8654.9661.6237.4533.8434.7234.9931.7528.9530.3527.98-27.16
PS Ratio
4.233.134.684.856.266.889.5512.8917.2916.1013.4013.4312.2412.9711.9710.3111.3611.4311.9010.57